Caplin Point Laboratories Ltd
CAPLIPOINTBSE 524742PharmaceuticalsMkt cap ₹20,009 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹610 Cr
YoY +19.6%QoQ +1.7%
Net profit · Q1 FY27
₹179 Cr
YoY +18.8%QoQ +3.6%
Net margin · Q1 FY27
29.3%
-0.2 pts vs Q1 FY26
Net profit · FY26
₹650 Cr
YoY +20.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 610 | 600 | 543 | 534 | 510 | +19.6% |
| Other income | 33.55 | 28.36 | 33.68 | 30.37 | 23.14 | +45.0% |
| Total income | 644 | 629 | 576 | 564 | 533 | +20.7% |
| Profit before tax | 225 | 213 | 204 | 201 | 184 | +22.1% |
| Tax | 46.13 | 40.56 | 38.03 | 40.77 | 33.70 | +36.9% |
| Net profit | 179 | 173 | 166 | 160 | 151 | +18.8% |
| Net margin | 29.3% | 28.8% | 30.6% | 30.0% | 29.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,187 | 1,937 | 1,694 | 1,467 | 1,269 | +12.9% |
| Other income | 116 | 96.43 | 66.94 | 55.98 | 38.75 | +19.8% |
| Total income | 2,303 | 2,034 | 1,761 | 1,523 | 1,308 | +13.2% |
| Profit before tax | 803 | 677 | 564 | 451 | 386 | +18.6% |
| Tax | 153 | 136 | 103 | 74.36 | 77.37 | +12.8% |
| Net profit | 650 | 541 | 461 | 377 | 308 | +20.1% |
| Net margin | 29.7% | 27.9% | 27.2% | 25.7% | 24.3% |
BIC's take
We haven't covered Caplin Point Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:56 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.